NO328465B1 - Krystallinsk monohydrat, fremgangsmate for fremstilling derav og anvendelse derav til fremstilling av et medikament - Google Patents
Krystallinsk monohydrat, fremgangsmate for fremstilling derav og anvendelse derav til fremstilling av et medikament Download PDFInfo
- Publication number
- NO328465B1 NO328465B1 NO20031694A NO20031694A NO328465B1 NO 328465 B1 NO328465 B1 NO 328465B1 NO 20031694 A NO20031694 A NO 20031694A NO 20031694 A NO20031694 A NO 20031694A NO 328465 B1 NO328465 B1 NO 328465B1
- Authority
- NO
- Norway
- Prior art keywords
- tiotropium bromide
- bromide monohydrate
- crystalline
- activated carbon
- water
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 10
- 230000008569 process Effects 0.000 title description 9
- 150000004682 monohydrates Chemical class 0.000 title description 4
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229960000257 tiotropium bromide Drugs 0.000 claims description 23
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 10
- 229940126601 medicinal product Drugs 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 3
- 238000010583 slow cooling Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000002076 thermal analysis method Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 description 9
- 239000013543 active substance Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000000227 grinding Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000001078 anti-cholinergic effect Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- -1 hydroxydi-2-thienylacetyl Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10050621 | 2000-10-12 | ||
| PCT/EP2001/011225 WO2002030928A1 (de) | 2000-10-12 | 2001-09-28 | Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031694D0 NO20031694D0 (no) | 2003-04-11 |
| NO20031694L NO20031694L (no) | 2003-04-11 |
| NO328465B1 true NO328465B1 (no) | 2010-02-22 |
Family
ID=7659568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031694A NO328465B1 (no) | 2000-10-12 | 2003-04-11 | Krystallinsk monohydrat, fremgangsmate for fremstilling derav og anvendelse derav til fremstilling av et medikament |
Country Status (47)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1401445E (pt) * | 2001-06-22 | 2006-10-31 | Boehringer Ingelheim Pharma | Anticolinergico cristalino, processo para a sua preparacao e sua utilizacao para a preparacao de um medicamento |
| US6608055B2 (en) | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US7311894B2 (en) | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| DE10214263A1 (de) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10317461A1 (de) | 2003-04-16 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung |
| UA82414C2 (uk) * | 2003-11-03 | 2008-04-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Солі тіотропію, спосіб їх одержання, а також лікарські композиції, які їх містять |
| BRPI0416136A (pt) * | 2003-11-03 | 2007-01-02 | Boehringer Ingelheim Int | processo para a produção de sais de tiotrópio, sais de tiotrópio, bem como formulações de medicamentos contendo os mesmos |
| SI1682542T1 (sl) * | 2003-11-03 | 2010-04-30 | Boehringer Ingelheim Int | Nov kristaliniŽŤen anhidrat z antiholinergiŽŤno uŽŤinkovitostjo |
| US7968717B2 (en) | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| DK1781298T3 (da) | 2004-04-22 | 2012-05-07 | Boehringer Ingelheim Int | Lægemiddelkombinationer indeholdende benzoxazin til behandling af luftvejs-sygdomme |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| ES2322148T3 (es) | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| DE102004048389A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa |
| UA95063C2 (ru) * | 2004-10-21 | 2011-07-11 | Бёрингер Ингельхайм Интернациональ Гмбх | Блистерная упаковка для применения в ингаляторах |
| EP1858554A2 (en) * | 2005-03-09 | 2007-11-28 | Boehringer Ingelheim International GmbH | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
| EP1877376A1 (de) | 2005-04-28 | 2008-01-16 | Boehringer Ingelheim International GmbH | Neue verbindungen zur behandlung von entzündlichen erkrankungen |
| BRPI0609295A2 (pt) | 2005-05-02 | 2010-03-23 | Boehringer Ingelheim Int | formas cristalinas de brometo de tiotràpio, composiÇço farmacÊutica, uso e mÉtodo para preparar as mesmas |
| RU2007144531A (ru) * | 2005-05-02 | 2009-06-10 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Новые кристаллические формы тиотропийбромида |
| WO2006134021A2 (en) * | 2005-06-15 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof |
| DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| BRPI0614394A2 (pt) * | 2005-08-06 | 2011-03-29 | Boehringer Ingelheim Int | uso de sais de tiotrópio |
| DK1917253T3 (da) | 2005-08-15 | 2015-03-30 | Boehringer Ingelheim Int | Fremgangsmåde til fremstilling af betamimetika |
| US20070086957A1 (en) | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| DE102005059602A1 (de) | 2005-12-14 | 2007-06-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Mikronisierung |
| MX2007009988A (es) | 2005-12-19 | 2008-02-22 | Sicor Inc | Formas novedosas de bromuro de tiotropio y procesos para su preparacion. |
| EP1966196A2 (en) * | 2005-12-19 | 2008-09-10 | Sicor, Inc. | Pure and stable tiotropium bromide |
| CN101355937A (zh) * | 2006-01-04 | 2009-01-28 | 贝林格尔·英格海姆国际有限公司 | 噻托铵盐在治疗中度持续性哮喘中的用途 |
| NZ563488A (en) | 2006-04-19 | 2010-04-30 | Boehringer Ingelheim Int | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| US20080051582A1 (en) | 2006-07-10 | 2008-02-28 | Sicor Inc. | Process for the preparation of tiotropium bromide |
| EP2051714B1 (de) | 2006-08-07 | 2011-04-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
| PE20080610A1 (es) | 2006-08-22 | 2008-07-15 | Boehringer Ingelheim Int | Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos |
| EP1923393A1 (en) * | 2006-11-17 | 2008-05-21 | Boehringer Ingelheim Pharma GmbH & Co. KG | Crystalline form of tiotropium bromide and urea |
| EP1925295A1 (de) | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stabile Pulverformulierung enthaltend ein Anticholinergikum |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| EA019480B1 (ru) | 2007-10-19 | 2014-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные пиперидинодигидротиенопиримидины в качестве ингибиторов pde4 |
| EP2093219A1 (de) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel |
| WO2010011813A1 (en) * | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
| CN103724328B (zh) | 2008-12-19 | 2015-10-14 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| EP2201934A1 (en) | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| EP2403851B1 (en) | 2009-03-06 | 2015-06-17 | Mahmut Bilgic | New crystalline forms of tiotropium bromide |
| WO2011015883A1 (en) | 2009-08-07 | 2011-02-10 | Generics [Uk] Limited | Dichloromethane solvate of tiotropium bromide and its use |
| CA2931876A1 (en) | 2009-08-07 | 2011-02-10 | Generics [Uk] Limited | Anhydrate of tiotropium bromide |
| MX2012006964A (es) | 2009-12-17 | 2012-07-17 | Boehringer Ingelheim Int | Nuevos antagonistas del receptor ccr2 y usos de los mismos. |
| JP5658272B2 (ja) | 2009-12-17 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２の新規アンタゴニスト及びこれらの使用 |
| NZ600857A (en) | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２アンタゴニスト及びこれらの使用 |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| EP2668177B1 (en) | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
| TR201102068A2 (tr) * | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropyum bromür içeren kristal maddeler |
| EP2721025B1 (en) | 2011-06-16 | 2015-11-25 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| EA024845B1 (ru) | 2011-07-26 | 2016-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные хинолины и их применение в качестве лекарственных средств |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| CZ304368B6 (cs) | 2011-11-28 | 2014-04-02 | Zentiva, K.S. | Směsný solvát tiotropium bromidu a způsob jeho přípravy |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| SI2914593T1 (sl) | 2012-11-05 | 2017-05-31 | Zentiva, K.S. | Stabilizacija tiotropijevih solvatov |
| EP2913332A1 (en) * | 2014-02-27 | 2015-09-02 | Euticals S.P.A. | Crystalline form of tiotropium bromide with lactose |
| EA032097B1 (ru) | 2014-03-19 | 2019-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероарильные ингибиторы syk |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| RU2567539C1 (ru) * | 2015-02-04 | 2015-11-10 | Индивидуальный предприниматель Михайлов Олег Ростиславович | КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ (1α,2β,4β,5α,7β-7)-[(ГИДРОКСИДИ-2-ТИЕНИЛАЦЕТИЛ)ОКСИ]-9,9-ДИМЕТИЛ-3-ОКСА-9-АЗОНИАТРИЦИКЛО[3.3.1.02,4]НОНАН БРОМИДА МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ |
| WO2017138896A1 (en) | 2016-02-11 | 2017-08-17 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti | Crystalline form of tiotropium bromide anhydrate |
| WO2018084817A2 (en) * | 2016-11-04 | 2018-05-11 | Si̇ma Patent Ve Li̇sanslama Hi̇zmetleri̇ Ltd. Şti̇ | A new form of active agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| GB2288978B (en) * | 1992-12-09 | 1997-04-09 | Boehringer Ingelheim Pharma | Hydrocarbon inhalant solutions stabilised by organic or inorganic acids |
| DE19834506A1 (de) * | 1998-07-31 | 2000-02-03 | Hexal Ag | Transmucosales therapeutisches System zur Anwendung von Sildenafil |
| WO2000007567A1 (de) * | 1998-08-04 | 2000-02-17 | Jago Research Ag | Medizinische aerosolformulierungen |
-
2001
- 2001-09-28 SK SK436-2003A patent/SK287009B6/sk not_active IP Right Cessation
- 2001-09-28 DK DK01983510T patent/DK1326862T3/da active
- 2001-09-28 CN CNB2005100977370A patent/CN100519558C/zh not_active Ceased
- 2001-09-28 AU AU2002214996A patent/AU2002214996B2/en not_active Expired
- 2001-09-28 DZ DZ013478A patent/DZ3478A1/fr active
- 2001-09-28 EP EP01983510A patent/EP1326862B1/de not_active Expired - Lifetime
- 2001-09-28 UA UA2003054185A patent/UA74215C2/uk unknown
- 2001-09-28 EA EA200300457A patent/EA004381B1/ru not_active IP Right Cessation
- 2001-09-28 DE DE50103666T patent/DE50103666D1/de not_active Expired - Lifetime
- 2001-09-28 BR BR0114584-3A patent/BR0114584A/pt active Pending
- 2001-09-28 NZ NZ525733A patent/NZ525733A/en not_active IP Right Cessation
- 2001-09-28 OA OA1200300107A patent/OA12403A/fr unknown
- 2001-09-28 CZ CZ20031025A patent/CZ301841B6/cs not_active IP Right Cessation
- 2001-09-28 MX MXPA03003221A patent/MXPA03003221A/es active IP Right Grant
- 2001-09-28 AT AT01983510T patent/ATE276253T1/de active
- 2001-09-28 ME MEP-2008-400A patent/ME00243B/me unknown
- 2001-09-28 HU HU0301022A patent/HU226830B1/hu unknown
- 2001-09-28 GE GE5214A patent/GEP20063905B/en unknown
- 2001-09-28 JP JP2002534314A patent/JP3764422B2/ja not_active Expired - Lifetime
- 2001-09-28 PL PL366041A patent/PL207870B1/pl unknown
- 2001-09-28 CN CNB018171435A patent/CN1221549C/zh not_active Ceased
- 2001-09-28 PT PT01983510T patent/PT1326862E/pt unknown
- 2001-09-28 KR KR1020037005083A patent/KR100823860B1/ko active IP Right Grant
- 2001-09-28 SI SI200130219T patent/SI1326862T1/xx unknown
- 2001-09-28 CA CA002425539A patent/CA2425539C/en not_active Expired - Lifetime
- 2001-09-28 EP EP04016877A patent/EP1468998A1/de not_active Withdrawn
- 2001-09-28 WO PCT/EP2001/011225 patent/WO2002030928A1/de active IP Right Grant
- 2001-09-28 IL IL15533501A patent/IL155335A0/xx active IP Right Grant
- 2001-09-28 AP APAP/P/2003/002775A patent/AP1572A/en active Active
- 2001-09-28 TR TR2004/02579T patent/TR200402579T4/xx unknown
- 2001-09-28 AU AU1499602A patent/AU1499602A/xx active Pending
- 2001-09-28 ME MEP-400/08A patent/MEP40008A/xx unknown
- 2001-09-28 EE EEP200300171A patent/EE04567B1/xx unknown
- 2001-09-28 RS YU27303A patent/RS50218B/sr unknown
- 2001-09-28 ES ES01983510T patent/ES2228965T3/es not_active Expired - Lifetime
- 2001-10-02 SA SA01220412A patent/SA01220412B1/ar unknown
- 2001-10-09 TW TW090124963A patent/TW589313B/zh active
- 2001-10-09 EG EG20011058A patent/EG24142A/xx active
- 2001-10-10 PE PE2001001000A patent/PE20020422A1/es active IP Right Grant
- 2001-10-10 MY MYPI20014705A patent/MY126931A/en unknown
- 2001-10-10 UY UY26962A patent/UY26962A1/es not_active Application Discontinuation
- 2001-10-12 AR ARP010104782A patent/AR034389A1/es active Pending
-
2003
- 2003-03-26 CR CR6938A patent/CR6938A/es unknown
- 2003-03-28 BG BG107687A patent/BG66161B1/bg active Active
- 2003-03-31 ZA ZA200302500A patent/ZA200302500B/en unknown
- 2003-04-07 EC EC2003004540A patent/ECSP034540A/es unknown
- 2003-04-08 MA MA27102A patent/MA25842A1/fr unknown
- 2003-04-09 IS IS6772A patent/IS2339B/is unknown
- 2003-04-10 IL IL155335A patent/IL155335A/en unknown
- 2003-04-10 HR HR20030276A patent/HRP20030276B1/xx not_active IP Right Cessation
- 2003-04-11 NO NO20031694A patent/NO328465B1/no not_active IP Right Cessation
-
2004
- 2004-05-20 HK HK04103583A patent/HK1060567A1/xx not_active IP Right Cessation
-
2006
- 2006-06-07 HK HK06106478.2A patent/HK1086557A1/xx not_active IP Right Cessation
-
2008
- 2008-09-19 AR ARP080104109A patent/AR068527A2/es unknown
-
2013
- 2013-07-11 UY UY34901A patent/UY34901A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328465B1 (no) | Krystallinsk monohydrat, fremgangsmate for fremstilling derav og anvendelse derav til fremstilling av et medikament | |
| US6777423B2 (en) | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | |
| CA2450961C (en) | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | |
| NO20190824A1 (no) | Krystallisk mikronisat av tiotropiumbromid | |
| US20040002510A1 (en) | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | |
| KR20130119844A (ko) | 글리코피로늄 클로라이드의 결정형 | |
| HRP20040890A2 (en) | Hfa-suspension formulation of an anhydrate | |
| WO2009135577A1 (en) | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |